Search results for "LUCA"

showing 10 items of 359 documents

Guerra giusta e guerra ingiusta nella Pharsalia di Lucano

2010

Bellum iustum Lucano PharsaliaSettore L-FIL-LET/04 - Lingua E Letteratura Latina
researchProduct

Biocompatibility, hemocompatibility and antimicrobial properties of xyloglucan-based hydrogel film for wound healing application.

2018

Crosslinked xyloglucan-poly(vinyl alcohol) based hydrogel films are interesting materials for wound healing applications. This work focuses on the hydrolytic degradation and consequent morphological modification of a XG-PVA film and on its interaction with cells, blood, bacteria. Biocompatibility of the film was assessed in vitro by investigating different aspects, such as cell viability, oxidative stress level, mitochondrial dysfunction and specific stress biomarkers. Partial adhesiveness was demonstrated by performing different attaching assays and phalloidin staining. Hemocompatibility of XG-PVA film after interaction with blood was evaluated by using a multi-parametric approach, includi…

BiocompatibilityadhesivenessBiocompatible Materials02 engineering and technologyFibrinogenPeripheral blood mononuclear cellBiochemistryHemocompatibility03 medical and health sciencesThrombinAnti-Infective AgentsIn vivoStructural BiologymedicineHumansPlateletViability assayMolecular BiologyGlucans030304 developmental biology0303 health sciencesBacterial growthHemostasisWound Healingintegumentary systemChemistryHydrolysisGeneral Medicine021001 nanoscience & nanotechnologyMethylgalactosidesAdhesiveneMitochondriaOxidative StressA549 CellsBiophysicsBiocompatibilityXylansSettore CHIM/07 - Fondamenti Chimici Delle Tecnologie0210 nano-technologyWound healingmedicine.drugInternational journal of biological macromolecules
researchProduct

Incretins, Pregnancy, and Gestational Diabetes

2015

The number of pregnant women affected by gestational diabetes mellitus (GDM) is increasing among Caucasians, and East Asians. GDM also increases the risk for later advent of type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease in both women and their offspring. The underlying mechanism of GDM is not fully elucidated. Incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), have been suggested to have a role in maternal metabolism and weight as well as fetal growth. These hormones might be implicated in mechanisms that compensate for the increment in glycemia and insulin resistance seen during pregnancy, while other factors, such a…

Blood Glucose0301 basic medicineendocrine systemmedicine.medical_specialtyendocrine system diseasesOffspringPharmaceutical ScienceIncretinGastric Inhibitory PolypeptideType 2 diabetes030204 cardiovascular system & hematologyIncretins03 medical and health sciences0302 clinical medicineInsulin resistanceGlucagon-Like Peptide 1PregnancyRisk FactorsInternal medicineGlucose IntoleranceAnimalsHumansMedicineObesityPregnancybusiness.industrynutritional and metabolic diseasesType 2 Diabetes MellitusType 2 diabetesIncretinmedicine.diseaseObesityGestational diabetesDiabetes Gestational030104 developmental biologyEndocrinologyGestational diabeteDiabetes Mellitus Type 2FemaleInsulin Resistancebusinesshormones hormone substitutes and hormone antagonistsBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome

2020

Abstract Glycemic variability (GV) has been recently described as an independent cardiovascular risk factor in patients with acute coronary syndrome (ACS). Also, new findings suggest that GV plays an important role in the development of complications related to impaired glucose metabolism and oxidative stress. On the other hand, although treatment for diabetes can reduce HbA1c in a similar extent their effectiveness over GV can be radically different. Patients in the acute setting of a coronary syndrome should be strictly monitorized to maintain glucose within recommended values; avoiding values lower than 90 mg/dL (5 mmol/L) and higher than 180 mg/dL (10 mmol/L). Also, evidence suggests th…

Blood Glucose0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeCarbohydrate metabolismmedicine.disease_causeGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusHumansInsulinMedicineAcute Coronary SyndromeRisk factorGlucagon-like peptide 1 receptorGlycemicbusiness.industryGeneral Medicinemedicine.diseaseOxidative StressGlucose030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2business030217 neurology & neurosurgeryOxidative stressMaceMedical Hypotheses
researchProduct

GLP2: An underestimated signal for improving glycaemic control and insulin sensitivity

2016

Glucagon-like peptide 2 (GLP2) is a proglucagon-derived peptide produced by intestinal enteroendocrine L-cells and by a discrete population of neurons in the brainstem, which projects mainly to the hypothalamus. The main biological actions of GLP2 are related to the regulation of energy absorption and maintenance of mucosal morphology, function and integrity of the intestine; however, recent experimental data suggest that GLP2 exerts beneficial effects on glucose metabolism, especially in conditions related to increased uptake of energy, such as obesity, at least in the animal model. Indeed, mice lacking GLP2 receptor selectively in hypothalamic neurons that express proopiomelanocortin show…

Blood Glucose0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulation030209 endocrinology & metabolismEnteroendocrine cellType 2 diabetesBiologyCarbohydrate metabolismDiet High-FatModels BiologicalType 2 diabeteMice03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineGlucagon-Like Peptide 2medicineAnimalsHomeostasisHumansGlucose homeostasisObesityeducationeducation.field_of_studyGLP2Insulin resistanceGlucagon-like peptide-2medicine.disease030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2GLP2; Insulin resistance; Obesity; Type 2 diabetes; Endocrinology; Endocrinology Diabetes and MetabolismHomeostasisSignal Transduction
researchProduct

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

2018

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially pr…

Blood GlucoseCardiometabolic parameterGlucagon-Like PeptidesIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticsIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEndothelial dysfunctionMolecular BiologyGlucagon-like peptide 1 receptorLiraglutidebusiness.industryType 2 Diabetes MellitusLiraglutideCardiovascular riskmedicine.diseasePlaque AtheroscleroticType 2 diabetes mellituBlood pressureDiabetes Mellitus Type 2Cardiovascular DiseasesMetabolic control analysisGlucagon-like peptide 1 receptor agonistMolecular Medicinebusinessmedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy

2022

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analyzed the effect of pasireotide (PAS) on glucose homeostasis. To assess gastro-entero-pancreatic hormones response in diabetic (DM+) and non-diabetic (DM–) patients, 26 patients with CD underwent an MMTT. Ten patients were submitted to a second MMTT after two months of PAS 600 µg twice daily. The DM+ group had significantly higher BMI, waist circumference, glycemia, HbA1c, ACTH le…

Blood GlucoseCushing’s disease; diabetes mellitus; incretin; mixed meal test tolerance test; pasireotidemixed meal test tolerance testGastric Inhibitory PolypeptideIncretinsCatalysisInorganic ChemistryGlucagon-Like Peptide 1HumansInsulinPhysical and Theoretical ChemistryPituitary ACTH HypersecretionMolecular BiologyMealsSpectroscopyGlycated HemoglobinpasireotideC-Peptidediabetes mellituOrganic Chemistrydigestive oral and skin physiologyGeneral MedicineCushing’s diseaseGlucagonincretinComputer Science ApplicationsDiabetes Mellitus Type 2Cushing’s disease; mixed meal test tolerance test; diabetes mellitus; incretin; pasireotidediabetes mellituspasireotide.Insulin ResistanceSomatostatinhormones hormone substitutes and hormone antagonists
researchProduct

Effect of Fibre-Enriched Orange Juice on Postprandial Glycaemic Response and Satiety in Healthy Individuals: An Acute, Randomised, Placebo-Controlled…

2019

Background: Consumption of fibre-enriched orange juice may be an appropriate way to supplement daily fibre intake and achieve beneficial effects on metabolic health. The present study aimed to assess the short-term effects of fibre-enriched orange juice on postprandial metabolism and satiety in a healthy adult population. Methods: In this double-blind, randomised, placebo-controlled, crossover study 10 healthy subjects underwent two one-day trials in which they consumed an orange juice beverage containing 1.4 g/100 mL of citrus fibre (29.3% soluble and 41.9% insoluble) or a placebo (regular orange juice without added fibre). Postprandial glucose, insulin, gut hormones (GLP1, GIP and ghrelin…

Blood GlucoseDietary FiberMale0301 basic medicineTime Factorsgut hormonesmedicine.medical_treatmentsatietyAppetite0302 clinical medicineBlood serumGlucagon-Like Peptide 1media_commonCross-Over StudiesNutrition and DieteticsLeptinglycaemiaPostprandial PeriodGhrelinHealthy VolunteersFruit and Vegetable JuicesPostprandialFemaleCitrus sinensisAdultmedicine.medical_specialtyinsulinmedia_common.quotation_subjectBlood sugar030209 endocrinology & metabolismSatiationArticlecitrus fibreYoung Adult03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansOrange juice030109 nutrition & dieteticsbusiness.industryInsulinAppetiteCrossover studyEndocrinologyGlycemic Indexorange juicehealthy subjectsbusinessFood ScienceNutrients
researchProduct

EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

2022

Type 2 diabetes mellitus (T2DM) is a serious public health concern as it is one of the most common chronic diseases worldwide due to social and economic developments that have led to unhealthy lifestyles, with a considerable impact both in terms of morbidity and mortality. The management of T2DM, before starting specific therapies, includes cornerstones such as healthy eating, regular exercise and weight loss. Strict adherence to the Mediterranean diet (MedDiet) has been related to an inverse association with the risk of T2DM onset, as well as an improvement in glycaemic control; in particular, thanks to the consumption of extra virgin olive oil (EVOO). Agonists of gut-derived glucagon-like…

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agent[SDV]Life Sciences [q-bio]Organic ChemistryEVOOT2DMGeneral MedicineIncretinIncretinsCatalysisComputer Science ApplicationsInorganic ChemistryDiabetes Mellitus Type 2Glucagon-Like Peptide 1Insulin SecretionHumansHypoglycemic AgentsMedDietPhysical and Theoretical ChemistryGLP-1Molecular BiologySpectroscopyHuman
researchProduct